638 related articles for article (PubMed ID: 24027332)
1. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.
Shirato K; Kawase M; Matsuyama S
J Virol; 2013 Dec; 87(23):12552-61. PubMed ID: 24027332
[TBL] [Abstract][Full Text] [Related]
2. Protease inhibitors targeting coronavirus and filovirus entry.
Zhou Y; Vedantham P; Lu K; Agudelo J; Carrion R; Nunneley JW; Barnard D; Pöhlmann S; McKerrow JH; Renslo AR; Simmons G
Antiviral Res; 2015 Apr; 116():76-84. PubMed ID: 25666761
[TBL] [Abstract][Full Text] [Related]
3. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
[TBL] [Abstract][Full Text] [Related]
4. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.
Kawase M; Shirato K; van der Hoek L; Taguchi F; Matsuyama S
J Virol; 2012 Jun; 86(12):6537-45. PubMed ID: 22496216
[TBL] [Abstract][Full Text] [Related]
6. Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry.
Shirato K; Kanou K; Kawase M; Matsuyama S
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733646
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
8. Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation.
Qian Z; Dominguez SR; Holmes KV
PLoS One; 2013; 8(10):e76469. PubMed ID: 24098509
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection.
Iwata-Yoshikawa N; Okamura T; Shimizu Y; Hasegawa H; Takeda M; Nagata N
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626688
[TBL] [Abstract][Full Text] [Related]
10. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
11. Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin during Viral Entry into Target Cells.
Matsuyama S; Shirato K; Kawase M; Terada Y; Kawachi K; Fukushi S; Kamitani W
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021905
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein.
Kleine-Weber H; Elzayat MT; Hoffmann M; Pöhlmann S
Sci Rep; 2018 Nov; 8(1):16597. PubMed ID: 30413791
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
14. The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases.
Earnest JT; Hantak MP; Li K; McCray PB; Perlman S; Gallagher T
PLoS Pathog; 2017 Jul; 13(7):e1006546. PubMed ID: 28759649
[TBL] [Abstract][Full Text] [Related]
15. Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures.
Guo W; Porter LM; Crozier TW; Coates M; Jha A; McKie M; Nathan JA; Lehner PJ; Greenwood EJ; McCaughan F
Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35110354
[TBL] [Abstract][Full Text] [Related]
16. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
Mahoney M; Damalanka VC; Tartell MA; Chung DH; Lourenço AL; Pwee D; Mayer Bridwell AE; Hoffmann M; Voss J; Karmakar P; Azouz NP; Klingler AM; Rothlauf PW; Thompson CE; Lee M; Klampfer L; Stallings CL; Rothenberg ME; Pöhlmann S; Whelan SPJ; O'Donoghue AJ; Craik CS; Janetka JW
Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34635581
[TBL] [Abstract][Full Text] [Related]
17. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
18. Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.
Icho S; Rujas E; Muthuraman K; Tam J; Liang H; Landreth S; Liao M; Falzarano D; Julien JP; Melnyk RA
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0043922. PubMed ID: 35703551
[TBL] [Abstract][Full Text] [Related]
19. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.
Yamamoto M; Matsuyama S; Li X; Takeda M; Kawaguchi Y; Inoue JI; Matsuda Z
Antimicrob Agents Chemother; 2016 Nov; 60(11):6532-6539. PubMed ID: 27550352
[TBL] [Abstract][Full Text] [Related]
20. ACE2 acts as a novel regulator of TMPRSS2-catalyzed proteolytic activation of influenza A virus in airway cells.
Heindl MR; Rupp A-L; Schwerdtner M; Bestle D; Harbig A; De Rocher A; Schmacke LC; Staker B; Steinmetzer T; Stein DA; Moulton HM; Böttcher-Friebertshäuser E
J Virol; 2024 Apr; 98(4):e0010224. PubMed ID: 38470058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
